Circulating trophoblast cell clusters for early detection of placenta accreta spectrum disorders-Reference-Cited by-全球学者库

Circulating trophoblast cell clusters for early detection of placenta accreta spectrum disorders

Published:2021-08-03 Issue:1 Volume:12 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Afshar Yalda,Dong Jiantong^ORCID,Zhao Pan,Li Lei,Wang Shan,Zhang Ryan Y.^ORCID,Zhang Ceng,Yin Ophelia^ORCID,Han Christina S.,Einerson Brett D.,Gonzalez Tania L.^ORCID,Zhang Huirong,Zhou Anqi^ORCID,Yang Zhuo^ORCID,Chou Shih-Jie,Sun Na^ORCID,Cheng Ju,Zhu Henan,Wang Jing^ORCID,Zhang Tiffany X.^ORCID,Lee Yi-Te^ORCID,Wang Jasmine J.,Teng Pai-Chi,Yang Peng^ORCID,Qi Dongping^ORCID,Zhao Meiping^ORCID,Sim Myung-Shin,Zhe Ruilian,Goldstein Jeffrey D.^ORCID,Williams John,Wang Xietong,Zhang Qingying,Platt Lawrence D.,Zou Chang^ORCID,Pisarska Margareta D.^ORCID,Tseng Hsian-Rong^ORCID,Zhu Yazhen^ORCID

Abstract

AbstractPlacenta accreta spectrum (PAS) is a high-risk obstetrical condition associated with significant morbidity and mortality. Current clinical screening modalities for PAS are not always conclusive. Here, we report a nanostructure-embedded microchip that efficiently enriches both single and clustered circulating trophoblasts (cTBs) from maternal blood for detecting PAS. We discover a uniquely high prevalence of cTB-clusters in PAS and subsequently optimize the device to preserve the intactness of these clusters. Our feasibility study on the enumeration of cTBs and cTB-clusters from 168 pregnant women demonstrates excellent diagnostic performance for distinguishing PAS from non-PAS. A logistic regression model is constructed using a training cohort and then cross-validated and tested using an independent cohort. The combined cTB assay achieves an Area Under ROC Curve of 0.942 (throughout gestation) and 0.924 (early gestation) for distinguishing PAS from non-PAS. Our assay holds the potential to improve current diagnostic modalities for the early detection of PAS.

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

https://www.nature.com/articles/s41467-021-24627-2.pdf

Reference51 articles.

1. Einerson, B. D. et al. Placenta accreta spectrum disorder: uterine dehiscence, not placental invasion. Obstet. Gynecol. 135, 1104–1111 (2020).

2. Silver, R. M. & Branch, D. W. Placenta accreta spectrum. N. Engl. J. Med. 378, 1529–1536 (2018).

3. Jauniaux, E. et al. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders. Int. J. Gynaecol. Obstet. 146, 20–24 (2019).

4. Society of Gynecologic, O. et al. Placenta accreta spectrum. Am. J. Obstet. Gynecol. 219, B2–B16 (2018).

5. Berkley, E. M. & Abuhamad, A. Z. Prenatal diagnosis of placenta accreta: Is sonography all we need? J. Ultrasound Med. 32, 1345–1350 (2013).

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Evolution of Management Strategies for Placenta Accreta Spectrum;Maternal-Fetal Medicine;2024-01-05

2. Continuous centrifugal microfluidics identifies the marker and size heterogeneity of circulating trophoblasts for accurate non-invasive prenatal diagnosis;Sensors and Actuators B: Chemical;2023-11

3. Interfacial Polymerization Produced Magnetic Particles with Nano‐Filopodia for Highly Accurate Liquid Biopsy in the PSA Gray Zone;Advanced Materials;2023-10-25

4. Pregnancy-specific beta-1-glycoprotein 6 is a potential novel diagnostic biomarker of placenta accreta spectrum;Medical Molecular Morphology;2023-10-13

5. Cell-based Noninvasive Prenatal Testing (cbNIPT)—A Review on the Current Developments and Future Prospects;Clinical Obstetrics & Gynecology;2023-07-17